Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Press ReleaseNicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial  Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025March 19, 2025 – release at 7:30 am CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the...

Biot, 19/03/2025 (informazione.it - comunicati stampa - salute e benessere)

 

 

Attachment